Spikevax Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rapid global vaccine deployment during pandemic, large-scale government immunization programs, advancement in mrna technology, expansion of vaccine manufacturing capacity, emergency regulatory authorizations.

The growth in the forecast period can be attributed to increasing focus on next-generation mrna vaccines, rising demand for variant-adapted immunizations, expansion of adult and pediatric vaccination coverage, growing investment in pandemic preparedness, continued innovation in vaccine delivery technologies. Major trends in the forecast period include increasing adoption of mrna vaccine platforms, expansion of variant-specific vaccine formulations, growing focus on booster immunization strategies, enhanced cold-chain optimization for vaccines, rising integration of digital immunization tracking.

The rising prevalence of COVID-19 cases is expected to drive the growth of the Spikevax market. COVID-19, caused by the SARS-CoV-2 virus, spreads through respiratory droplets and can cause symptoms ranging from mild fever to severe respiratory complications. Factors such as new viral variants, waning immunity, relaxed restrictions, seasonal indoor gatherings, and uneven vaccine coverage are contributing to the increase in cases. Spikevax combats COVID-19 by using mRNA technology to induce the production of the viral spike protein, training the immune system to recognize and fight the virus, thereby offering protection against severe disease and emerging variants. For instance, in March 2023, the Office for National Statistics in the UK reported that approximately 1.9 million people (2.9% of the population) experienced long COVID, with 92% having had COVID-19 over 12 weeks earlier, 69% experiencing symptoms for over a year, and 41% for over two years. Therefore, the rising prevalence of COVID-19 is propelling the Spikevax market forward.

The increase in healthcare investments is also expected to support the growth of the Spikevax market. Healthcare investments, which encompass spending on treatments, medications, hospital care, and public health infrastructure, are rising due to an aging population, growing healthcare needs, technological advancements, and higher service and medication costs. These investments facilitate the adoption of Spikevax by funding vaccine procurement, enhancing distribution infrastructure, and improving delivery systems, ensuring broader accessibility and supporting public health initiatives. For instance, in May 2024, the UK’s Office for National Statistics reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, compared to 0.9% in 2022. Therefore, growing healthcare investments are driving the Spikevax market.

In September 2024, Moderna, Inc., a U.S.-based biotechnology company, entered into a joint commercialization agreement with Cenra Healthcare for its mRNA respiratory vaccine portfolio, including Spikevax (mRNA-1273). Under this agreement, Moderna leads manufacturing, distribution, and supply, while Cenra Healthcare, a Taiwan-based company specializing in healthcare services, government contracting, and biologics commercialization, handles local medical education, promotion, and market access. This partnership aims to expand Spikevax availability and strengthen its market presence in Taiwan.

Major companies operating in the spikevax market are Moderna Inc.

North America was the largest region in the spikevax market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spikevax market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spikevax market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the spikevax market by increasing costs of imported lipid nanoparticles, nucleotides, cold-chain storage equipment, specialized vials, and high-precision manufacturing machinery used in mRNA vaccine production. North America and Europe are most affected due to complex global sourcing of vaccine components, while Asia-Pacific faces export-related cost pressures. These tariffs contribute to higher manufacturing and distribution expenses and influence vaccine pricing negotiations. However, they are also driving domestic mRNA manufacturing investments, regional vaccine production expansion, and long-term resilience of immunization supply chains.

The spikevax market research report is one of a series of new reports that provides spikevax market statistics, including spikevax industry global market size, regional shares, competitors with a spikevax market share, detailed spikevax market segments, market trends and opportunities, and any further data you may need to thrive in the spikevax industry. This spikevax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spikevax is a vaccine developed to prevent COVID-19 in individuals aged 6 months and older. It contains elasomeran, an mRNA molecule that provides genetic instructions for cells to produce the spike protein of the original SARS-CoV-2 strain, enabling the immune system to recognize and respond to the virus.

The primary clinical indication for Spikevax is COVID-19, a viral respiratory disease caused by SARS-CoV-2, which can cause symptoms such as fever, cough, and breathing difficulties. Spikevax works by instructing cells to produce a protein similar to the virus’s spike protein, helping the immune system respond effectively if exposed. The vaccine is available in formulations including Spikevax Original, Spikevax Bivalent (Original or Omicron), and Spikevax XBB.1.5. It is distributed through government channels, hospitals, and clinics and is used by adults, adolescents, and children.

The spikevax market consists of sales of COVID-19 vaccines, bivalent booster vaccines, syringes, and needles. Values in this market are ‘factory gate’ values, representing the value of vaccines sold directly by manufacturers, either to governments, healthcare organizations, or distribution networks. This includes revenues from related services but excludes resales further along the supply chain or integration into other healthcare products.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.